medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2008, Número 1

Siguiente >>

Rev Invest Clin 2008; 60 (1)


Factores asociados con microalbuminuria en pacientes diabéticos tipo 2 no hipertensos

López-Arce G, Espinoza-Peralta D, Hernández-Alarcón A, Arce-Salinas CA

Idioma: Español
Referencias bibliográficas: 45
Paginas: 4-10
Archivo PDF: 67.65 Kb.


RESUMEN

Introducción. Se ha verificado que la microalbuminuria es un factor de riesgo para eventos cardiovasculares y progresión de daño renal en pacientes diabéticos. Valoramos los factores relacionados con la presencia de microalbuminuria en diabéticos tipo 2 sin hipertensión arterial y sin otra medicación Objetivo. Comparar los factores relacionados con la presencia de microalbuminuria en pacientes con diabetes mellitus tipo 2 sin hipertensión arterial. Material y métodos. Se realizó una evaluación transversal de un grupo de pacientes diabéticos con y sin microalbuminuria. Para el análisis se incluyeron variables antropométricas, realización de ejercicio, consumo de alcohol y tabaco; depuración de creatinina, HbA1c, promedio de glucemias semestrales en los dos años previos y nivel lípidos; se estimó además la ingestión calórica y proteínica en 24 h. Resultados. De los 86 sujetos, 19 presentaron microalbuminuria y ésta se relacionó con mayor tiempo de evolución de diabetes (114 ± 55 vs. 84 ± 67 meses; p = 0.03), mayores niveles de HbA1c (8.9 vs. 7.1%; p = 0.001) y menores niveles de colesterol HDL (37.7 ± 11 vs. 42.9 ± 12 mg/dL; p = 0.03). En el análisis multivariado la HbA1c y los niveles de glucosa mantuvieron significancia. Conclusión. En sujetos con diabetes mellitus tipo 2 normotensos, el descontrol crónico de la glucosa y el tiempo de evolución se relacionan con la presencia de microalbuminuria; no así el IMC, la dieta, ejercicio, consumo de tabaco y alcohol.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Zimmet P, Alberti KG, Shawn J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.

  2. http://www.usrds.org/adr.htm (en linea).

  3. Barsoum R. Chronic kidney disease in the developing world. N Engl J Med 2006; 354: 997-9.

  4. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999; 341: 1127-33.

  5. Deferrari G, Repetto M, Calvi C, et al. Diabetic nephropathy: from micro- to macroalbuminuria. Nephrol Dial Transplant 1998; 13: 11-5.

  6. Walls J. Relationship between proteinuria and progressive renal disease. Am J Kidney Dis 2001; 37(Suppl. 2): S13-S6.

  7. Meigs JB, D’Agostino RB, Nathan DM, et al. Longitudinal association of glycemia and microalbuminuria. The Framingham Offspring Study. Diabetes Care 2002; 25: 977-83.

  8. Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-8.

  9. Murray E, Vito C. Pleiotropic effects of 3-hidroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005; 45: 2-14.

  10. Stern MP. Diabetes and cardiovascular disease: the “common soil” hypothesis. Diabetes 1995; 44: 369-74.

  11. Jiménez CA, Rivera MD, Hernández AM, et al. Microalbuminuria as a predictor of myocardial infarction in a Mexican population: The Mexico City Diabetes Study. Kidney International 2005; 68(Suppl. 97): S34-9.

  12. Rosas M, Attie F, Pastelin G, et al. Prevalance of proteinuria in Mexico: A conjunctive consolidation approach with other cardiovascular risk factors: The Mexican Health Survey 2000. Kidney International 2005; 68(Suppl. 97): S112-9.

  13. Cueto-Manzano AM, Cortés-Sanabria LC, Martínez-Ramírez R, et al. Detection of early nephropathy in Mexican patients with type 2 diabetes mellitus. Kidney International 2005; 68(Suppl. 97): S40-5.

  14. Aguilar-Salinas C, Velázquez MO, Gómez-Pérez FJ, et al. Characteristics of patients with type 2 diabetes in Mexico. Diabetes Care 2003; 26: 2021-6.

  15. Villalpando GC, Stern MP, Arredondo PB, et al. Nephropathy in low income diabetics: the Mexico City Diabetes Study. Arch Med Res 1996; 27: 367-72.

  16. Wrone E, Carnethon MR, Palaniappan L, et al. Association of dietary protein intake and microalbuminuria in healthy adults: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 580-7.

  17. Orchard TJ, Chang YF, Ferrell RE, et al. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 2002; 62: 963-70.

  18. Mykkanen L, Zaccaro DJ, Wagenknecht LE, et al. Microalbuminuria is associated with insulin resistance in non-diabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47: 793-800.

  19. Mogensen CE, Viberti G, Halimi S, et al. Effect of Low-Dose Perindopril/Indapamide on Albuminuria in Diabetes. Hypertension 2003; 41: 1063-71.

  20. Douglas K, O’Malley PG, Jackson JL. Meta-Analysis: The Effect of Statins on Albuminuria. Ann Intern Med 2006; 145: 117-24.

  21. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care 2006; 29(Suppl. 1): S4-42.

  22. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-71.

  23. Departamento de Ciencia y Tecnología de Alimentos, Departamento de Informática en Investigación. Tablas de composición de alimentos mexicanos. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. México, D.F. 1998 (Disponible en: http://www.innsz.mx/alimentos/cd.html).

  24. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function- measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-83.

  25. Cooper ME, Jandeleit-Dahm K, Thomas MC. Targets to retard the progression of diabetic nephropathy. Kidney Int 2005; 68: 1439-45.

  26. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995; 47: 1703-20.

  27. Ruggenenti P, Remuzzi G. Microalbuminuria, time to abandon. Kidney Int 2006; 70: 1214-22.

  28. Manaviat MR, Afkhami M, Shoja MR. Retinopathy and microalbuminuria in type II diabetic patients. BMC Ophthalmol 2004; 4-9.

  29. Deferrari G. Treatment of diabetic nephropathy in its early stages. Diabetes Metabol Rev 1997; 13: 51-61.

  30. Colhoun HM, Lee ET, Bennett PH, et al. Risk factors for renal failure: The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44(Suppl. 2): S46-S53.

  31. Hsu C, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21-8.

  32. Zandbergen AAM, Sijbrands J, et al. Normotensive Women with type 2 Diabetes and microalbuminuria are at high risk for macrovascular disease. Diabetes Care 2006; 29: 1851-5.

  33. Kohler K, McClellan WM, Ziemer DC, et al. Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. Am J Kidney Dis 2000; 36: 903-13.

  34. Nosadini R, Velussi M, Brocco E, et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes 2000; 49: 476-84.

  35. Lassila M, Seah KK, Allen TJ, et al. Accelerated nephropathy in diabetic apolipoprotein E- knockout mouse: Role of advanced glycation end products. J Am Soc Nephrol 2004; 15: 2125-38.

  36. Eto M, Sato M, Okada M, et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002; 40: 243-51.

  37. Molitch ME, Rupp D, Carnethon M. Higher levels of HDLcholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes. Diabetes Care 2006; 29: 78-82.

  38. Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia: a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 1994; (Suppl. 45): S125-31.

  39. Domínguez JH, Tang N, Xu W, et al. Studies of renal injury III: Lipid-induced nephropathy in type II diabetes. Kidney Int 2000; 57: 92-104.

  40. Nosadini R, Tonolo G. Blood glucose and lipid control as risk factors in the progression of renal damage in type 2 diabetes. J Nephrol 2003; 16(Suppl.): S42-47.

  41. Geluk C, Asselbergs F, Hillege H. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND intervention trial. Eur Heart J 2005; 26: 1249-51.

  42. Hommel E, Andersen P, Gall MA, et al. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 1992; 35: 447-51.

  43. Lintott CJ, Scott RS, Bremer JM, et al. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Am J Cardiol 1995; 76: 97A-101A.

  44. Nielsen S, Schmitz O, Moller N. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulindependent) diabetic patients with microalbuminuria. Diabetologia 1993; 36: 1079-86.

  45. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowsky lecture 2005. Diabetologia 2006; 49: 11-19.




2020     |     www.medigraphic.com